Navigation Links
Proteolix Raises $79 Million in Series C Financing
Date:9/8/2008

Funds to Support Clinical Development of Carfilzomib

Paul Hastings Appointed to Board of Directors

SOUTH SAN FRANCISCO, Calif., Sept. 8 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the successful completion of a new financing round of $79 million. The Series C round was led by new investor Nomura Phase4 Ventures. New investor Westfield Capital Management and existing investors, Advanced Technology Ventures, Delphi Ventures, Latterell Venture Partners, U.S. Venture Partners and The Vertical Group, all participated in the financing.

Proceeds from the financing will primarily support the completion of the company's ongoing Phase 2 clinical trials of carfilzomib, and the advancement of this anti-cancer therapeutic into Phase 3 clinical trials for the treatment of multiple myeloma. Proteolix will also use the funds to advance candidates in the company's earlier stage pipeline of proteasome inhibitors.

"We are pleased to have completed this significant financing with participation from such highly-regarded new and existing investors," said Susan Molineaux, Ph.D., Proteolix's Chief Executive Officer. "Our lead candidate, carfilzomib, has demonstrated promising results in clinical and preclinical studies in multiple myeloma and a variety of other tumor types. Proceeds from this financing will enable us to advance carfilzomib to registration studies for multiple myeloma while continuing to cultivate select early-stage assets in our pipeline."

"We have been impressed by Proteolix's team, pipeline and proprietary expertise in the area of proteasome drug discovery and development. In particular, carfilzomib has been designed to be a highly selective candidate against a validated target and has demonstrated promising clinical data in hematologic malignancies," said Denise Pollar
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. Pearl Therapeutics Raises $15.5 Million in Private Financing
4. Enobia Pharma Raises $40.1 Million Series B Financing
5. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
6. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
7. VisEn Medical Raises $7 Million in Series B Financing
8. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
9. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
(Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... up by 48% at EUR958 Million - EBITDA Margin ... the Target Segment of Pharmaceutical Plastics,in South America: Brazilian ... to provisional figures, Gerresheimer AG has just completed,another record ... up by,48.1%; the adjusted Group EBITDA margin reached 19%. ...
... think a lot about "Homeland Security," but one Montana ... home gardeners also serves to keep us safe from ... the Bozeman campus recently received a five-year grant for ... the lab provides an early warning system of biological ...
... manufactured product our clothes, money, appliances, the paint ... cars will be embedded with intelligence, networks of ... dust or an Internet of Things. The world of ... have surveillance systems, biometrics, personal communicators, machine learning and ...
Cached Biology Technology:2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer 22007 Another Record Year in Terms of Sales and Earnings for Gerresheimer 3Montana State University lab gives early warnings about biological invaders 2Montana State University lab gives early warnings about biological invaders 3Supportive devices or unnecessary surveillance? 2
(Date:7/11/2014)... started near the City of Entiat on Tuesday, July ... fire quickly grew to over 1,000 acres by evening. ... is under investigation by the Washington Department of Natural ... local resources in developing fire control strategies and tactics. ... State Department of Natural Resources, (WA DNR), Bureau of ...
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... with other group members to reduce aggression and gain ... strategy for grooming activities shows a certain pattern across ... scientific journal Biology Letters . , Grooming between ... without ulterior motives. To be groomed has hygienic benefits ... another individual can provide access to infants, mating opportunities ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2
... Boston, Mass. A computational physicist and a cognitive ... the beginnings of a noninvasive test to evaluate an ... which records electrical activity in the brain, with machine-learning ... percent accuracy in distinguishing between 9-month-old infants known to ...
... cycle, helping sequester significant amounts of carbon. Some algal ... discolor coastal waters and reduce the amount of light ... "red tide," the term "harmful algal blooms" (HABs) was ... biomass can sometimes also turn the ocean waters brown ...
... Cross-disciplinary teams of scientists studying genetic pathways that ... also cause certain forms of congenital heart disease ... muscle that is the leading cause of sudden death ... mutations into mice and successfully treated HCM in the ...
Cached Biology News:Using EEGs to diagnose autism spectrum disorders in infants 2Using EEGs to diagnose autism spectrum disorders in infants 3Brown tide culprit sequenced: Genome of the first of algal bloom species 2Brown tide culprit sequenced: Genome of the first of algal bloom species 3Brown tide culprit sequenced: Genome of the first of algal bloom species 4Cancer-related pathways reveal potential treatment target for congenital heart disease 2Cancer-related pathways reveal potential treatment target for congenital heart disease 3